Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01390220 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters
A Phase 3 study, sponsored by UCB Biopharma S.P.R.L..
- Terminated
- Registry status
- Phase 3
- Development phase
- 292
- Enrollment target
NCT01390220 is a Phase 3 study that was terminated before completion, run by UCB Biopharma S.P.R.L.. The registered enrollment target is 292 participants.
The verdict
NCT01390220, a Phase 3 study, was terminated before completion, sponsored by UCB Biopharma S.P.R.L..
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 292 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the safety and effectiveness of USL261 for the outpatient treatment of seizure clusters.
Interventions
- DRUG Placebo
- DRUG USL261
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 292 participants |
| Start Date | 2011-06 |
| Est. Completion | 2017-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01390220
The ClinicalTrials.gov registry entry for NCT01390220 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 292 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma S.P.R.L., which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01390220 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01390220 about?
NCT01390220 is a clinical study titled "Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters". The purpose of this study is to examine the safety and effectiveness of USL261 for the outpatient treatment of seizure clusters.
What is the current status of trial NCT01390220?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 292 participants. The study started on 2011-06. Estimated completion is 2017-03.
What interventions are being tested in trial NCT01390220?
The interventions under investigation include: Placebo (DRUG), USL261 (DRUG).
Who is sponsoring clinical trial NCT01390220?
This trial is sponsored by UCB Biopharma S.P.R.L., which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.